文献速递胸部肿瘤头颈与中枢神经肿瘤

非小细胞肺癌脑转移患者接受检查点抑制剂治疗的结局

Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.
PubMed 文献 · J Thorac Oncol · 2019-02-16

在1025例接受ICI治疗的晚期NSCLC患者中,255例(24.9%)有脑转移;有无脑转移的ORR相似(20.6% vs 22.7%,p=0.484),但脑转移组中位PFS(1.7 vs 2.1个月,p=0.009)和OS(8.6 vs 11.4个月,p=0.035)较短;多因素分析中脑转移与生存无关,稳定脑转移、未用皮质类固醇及较高ds-GPA评分预后较好。

要点

  • ICI治疗的NSCLC患者中脑转移者占24.9%,有无脑转移的ORR相似(20.6% vs 22.7%,p=0.484)。
  • 脑转移组中位PFS 1.7个月 vs 无脑转移组2.1个月(p=0.009),中位OS 8.6 vs 11.4个月(p=0.035)。
  • 脑转移亚组多因素分析中,使用皮质类固醇与较差OS相关(HR=2.37),稳定脑转移(HR=0.62)和较高ds-GPA分级(HR=0.48-0.52)与较好OS相关。

核心结论

  • 多因素分析中,脑转移与接受ICI治疗的NSCLC患者较差的生存无关。
  • 无基线皮质类固醇且ds-GPA分级良好的稳定脑转移患者预后最佳。

研究设计与样本

  • 连续纳入接受ICI治疗的晚期NSCLC患者,收集数据。
  • 共纳入1025例患者,从ICI治疗开始的中位随访时间为15.8个月。
  • 活动性脑转移定义为ICI治疗开始前新出现和/或增大的病灶且未接受后续局部治疗。
  • 评估客观缓解率(ORR)、无进展生存期和总生存期(OS)。
  • 采用Cox比例风险模型和逻辑回归进行多因素分析。

主要发现

  • 255例(24.9%)有脑转移,其中39.2%为活动性脑转移,14.3%有症状,27.4%正在接受皮质类固醇治疗。
  • 94.5%的患者已知疾病特异性分级预后评估(ds-GPA)评分:35.7%评分为0-1,58.5%评分为1.5-2.5,5.8%评分为3。
  • 有脑转移 vs 无脑转移的ORR相似:20.6% vs 22.7%(p=0.484)。
  • 活动性脑转移且有随访脑影像的患者(n=73)颅内ORR为27.3%。
  • 有脑转移 vs 无脑转移的中位PFS分别为1.7个月(95%CI:1.5-2.1) vs 2.1个月(95%CI:1.9-2.5)(p=0.009)。

关键数值与推荐

  • 脑转移患者中12.7%出现颅内外分离缓解,2例(0.8%)出现脑假性进展。
  • 活动性脑转移 vs 稳定性脑转移的脑进展发生率分别为54.2% vs 30%(p<0.001)。
  • 脑转移亚组多因素分析中,使用皮质类固醇与较差的OS相关(HR=2.37)。
  • 脑转移亚组多因素分析中,稳定性脑转移(HR=0.62)和较高ds-GPA分级(HR=0.48-0.52)与改善的OS相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Although frequent in NSCLC, patients with brain metastases (BMs) are often excluded from immune checkpoint inhibitor (ICI) trials. We evaluated BM outcome in a less-selected NSCLC cohort. METHODS: Data from consecutive patients with advanced ICI-treated NSCLC were collected. Active BMs were defined as new and/or growing lesions without any subsequent local treatment before the start of ICI treatment. Objective response rate (ORR), progression-free survival, and overall survival (OS) were evaluated. Multivariate analyses were performed by using a Cox proportional hazards model and logistic regression. RESULTS: A total of 1025 patients were included; the median follow-up time from start of ICI treatment was 15.8 months. Of these patients, 255 (24.9%) had BMs (39.2% active, 14.3% symptomatic, and 27.4% being treated with steroids). Disease-specific Graded Prognostic Assessment (ds-GPA) score was known for 94.5% of patients (35.7% with a score of 0-1, 58.5% with a score of 1.5-2.5, and 5.8% with a score of 3). The ORRs with BM versus without BM were similar: 20.6% (with BM) versus 22.7% (without BM) (p = 0.484). The intracranial ORR (active BM with follow-up brain imaging [n = 73]) was 27.3%. The median progression-free survival times were 1.7 (95% confidence interval [CI]: 1.5-2.1) and 2.1 (95% CI: 1.9-2.5) months, respectively (p = 0.009). Of the patients with BMs, 12.7% had a dissociated cranial-extracranial response and two (0.8%) had brain pseudoprogression. Brain progression occurred more in active BM than in stable BM (54.2% versus 30% [p < 0.001]). The median OS times were 8.6 months (95% CI: 6.8-12.0) with BM and 11.4 months (95% CI: 8.6-13.8) months with no BM (p = 0.035). In the BM subgroup multivariate analysis, corticosteroid use (hazard ratio [HR] = 2.37) was associated with poorer OS, whereas stable BMs (HR = 0.62) and higher ds-GPA classification (HR = 0.48-0.52) were associated with improved OS. CONCLUSION: In multivariate analysis BMs are not associated with a poorer survival in patients with ICI-treated NSCLC. Stable patients with BM without baseline corticosteroids and a good ds-GPA classification have the best prognosis.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Hendriks LEL, Henon C, Auclin E, et al. Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors. J Thorac Oncol. 2019. PMID: 30780002. doi:10.1016/j.jtho.2019.02.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。